Tags

Type your tag names separated by a space and hit enter

Cannabinoid pharmacology and therapy in gut disorders.
Biochem Pharmacol. 2018 11; 157:134-147.BP

Abstract

Cannabis sp. and their products (marijuana, hashish…), in addition to their recreational, industrial and other uses, have a long history for their use as a remedy for symptoms related with gastrointestinal diseases. After many reports suggesting these beneficial effects, it was not surprising to discover that the gastrointestinal tract expresses endogenous cannabinoids, their receptors, and enzymes for their synthesis and degradation, comprising the so-called endocannabinoid system. This system participates in the control of tissue homeostasis and important intestinal functions like motor and sensory activity, nausea, emesis, the maintenance of the epithelial barrier integrity, and the correct cellular microenvironment. Thus, different cannabinoid-related pharmacological agents may be useful to treat the main digestive pathologies. To name a few examples, in irritable bowel syndrome they may normalize dysmotility and reduce pain, in inflammatory bowel disease they may decrease inflammation, and in colorectal cancer, apart from alleviating some symptoms, they may play a role in the regulation of the cell niche. This review summarizes the main recent findings on the role of cannabinoid receptors, their synthetic or natural ligands and their metabolizing enzymes in normal gastrointestinal function and in disorders including irritable bowel syndrome, inflammatory bowel disease, colon cancer and gastrointestinal chemotherapy-induced adverse effects (nausea/vomiting, constipation, diarrhea).

Authors+Show Affiliations

Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; Unidad Asociada I+D+i al Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC), Spain; Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo Multidisciplinar de Investigación y Tratamiento del Dolor (i+DOL), Spain.Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; Unidad Asociada I+D+i al Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC), Spain; Unidad Asociada I+D+i al Instituto de Química Médica, IQM (CSIC), Spain; Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo Multidisciplinar de Investigación y Tratamiento del Dolor (i+DOL), Spain.Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; Unidad Asociada I+D+i al Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC), Spain; Unidad Asociada I+D+i al Instituto de Química Médica, IQM (CSIC), Spain; Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo Multidisciplinar de Investigación y Tratamiento del Dolor (i+DOL), Spain. Electronic address: raquel.abalo@urjc.es.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30076849

Citation

Uranga, J A., et al. "Cannabinoid Pharmacology and Therapy in Gut Disorders." Biochemical Pharmacology, vol. 157, 2018, pp. 134-147.
Uranga JA, Vera G, Abalo R. Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018;157:134-147.
Uranga, J. A., Vera, G., & Abalo, R. (2018). Cannabinoid pharmacology and therapy in gut disorders. Biochemical Pharmacology, 157, 134-147. https://doi.org/10.1016/j.bcp.2018.07.048
Uranga JA, Vera G, Abalo R. Cannabinoid Pharmacology and Therapy in Gut Disorders. Biochem Pharmacol. 2018;157:134-147. PubMed PMID: 30076849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid pharmacology and therapy in gut disorders. AU - Uranga,J A, AU - Vera,G, AU - Abalo,R, Y1 - 2018/08/02/ PY - 2018/05/31/received PY - 2018/07/31/accepted PY - 2018/8/5/pubmed PY - 2019/7/10/medline PY - 2018/8/5/entrez KW - Cannabinoid KW - Chemotherapy-induced adverse effects KW - Colorectal cancer KW - Inflammatory bowel disease KW - Irritable bowel syndrome SP - 134 EP - 147 JF - Biochemical pharmacology JO - Biochem. Pharmacol. VL - 157 N2 - Cannabis sp. and their products (marijuana, hashish…), in addition to their recreational, industrial and other uses, have a long history for their use as a remedy for symptoms related with gastrointestinal diseases. After many reports suggesting these beneficial effects, it was not surprising to discover that the gastrointestinal tract expresses endogenous cannabinoids, their receptors, and enzymes for their synthesis and degradation, comprising the so-called endocannabinoid system. This system participates in the control of tissue homeostasis and important intestinal functions like motor and sensory activity, nausea, emesis, the maintenance of the epithelial barrier integrity, and the correct cellular microenvironment. Thus, different cannabinoid-related pharmacological agents may be useful to treat the main digestive pathologies. To name a few examples, in irritable bowel syndrome they may normalize dysmotility and reduce pain, in inflammatory bowel disease they may decrease inflammation, and in colorectal cancer, apart from alleviating some symptoms, they may play a role in the regulation of the cell niche. This review summarizes the main recent findings on the role of cannabinoid receptors, their synthetic or natural ligands and their metabolizing enzymes in normal gastrointestinal function and in disorders including irritable bowel syndrome, inflammatory bowel disease, colon cancer and gastrointestinal chemotherapy-induced adverse effects (nausea/vomiting, constipation, diarrhea). SN - 1873-2968 UR - https://www.unboundmedicine.com/medline/citation/30076849/Cannabinoid_pharmacology_and_therapy_in_gut_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-2952(18)30318-6 DB - PRIME DP - Unbound Medicine ER -